Infliximab in inflammatory bowel disease.

"Conflict of interest statement: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: A.S.C. has served on advisory boards for Abbvie, Janssen Takeda, Pfizer, Arena, Samsung, Grifols, and Bacainn and has received research support from Miraca. The remaining authors declare no conflict of interest."

"Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: K.P. is supported by a Ruth L. Kirschstein NRSA Institutional Research Training Grant 5T32DK007760-18. The content of this project is solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health (NIH)."